Home›The Library›Pozelimab
Pozelimab (Veopoz)
Pozelimab is a fourth complement-C5 antibody in the cluster this site's eculizumab & ravulizumab and crovalimab pages already cover — but instead of treating paroxysmal nocturnal hemoglobinuria, it's approved for an entirely different, far rarer disease: CHAPLE syndrome, a hereditary complement disorder so uncommon that fewer than 10 patients had been identified in the United States by the time of its 2023 FDA approval. That approval rested on an open-label trial of just 10 patients — no placebo arm, no randomization, no comparator drug — a genuinely unusual evidentiary bar the FDA accepted specifically because a disease this rare, and this severe in its natural history, made a conventional controlled trial practically impossible to run.
On this page
In brief
Should you care? Relevant mainly if you or a family member has CHAPLE disease, an ultra-rare inherited complement disorder — this isn't a mainstream drug, but it's a real, FDA-approved biologic worth understanding alongside this site's eculizumab & ravulizumab and crovalimab pages on the same drug target.The short version
- What it is: a fully human IgG4 monoclonal antibody against complement C5, developed by Regeneron using the same VelocImmune antibody-discovery platform behind several of the company's other approved drugs — blocking terminal complement activation, the same mechanism as eculizumab, ravulizumab and crovalimab, but for a different disease entirely.
- Evidence: a 10-patient, open-label Phase 2/3 trial (no placebo group) found all 10 patients achieved and sustained normal serum albumin and IgG levels through at least 72 weeks of treatment.
- The real story: CHAPLE disease is so rare that fewer than 10 patients had been identified in the entire US as of Veopoz's 2023 approval — the FDA accepted an evidentiary bar (a single-arm trial with no internal comparator) that would be unacceptable for almost any other approval, because the disease's own documented natural history made withholding treatment from a placebo group ethically and practically untenable.
A fourth anti-C5 antibody, for a disease almost nobody has
This site's eculizumab & ravulizumab page and crovalimab page describe three antibodies that block complement protein C5 to treat paroxysmal nocturnal hemoglobinuria (PNH) and related complement-driven blood disorders. Pozelimab, developed by Regeneron using its VelocImmune fully-human-antibody platform, blocks the same target but treats a different disease: CHAPLE syndrome (CD55-deficient protein-losing enteropathy, also called CHAPLE disease), an ultra-rare inherited disorder in which loss-of-function mutations in the CD55 gene leave patients unable to regulate their own complement system. Without CD55 acting as a brake, complement activity runs unchecked, driving chronic intestinal inflammation, protein-losing enteropathy (the gut leaking essential blood proteins like albumin and immunoglobulin faster than the body can replace them), recurrent infections, and abnormal blood clotting. The FDA approved pozelimab as Veopoz (pozelimab-bbfg, BLA 761339) on 18 August 2023, for patients 1 year of age and older — the first treatment ever approved for CHAPLE disease, and, per Regeneron's own public statements, a disease with fewer than 10 identified patients in the United States at the time of approval.
The evidence: 10 patients, no placebo, no comparator
Pozelimab's approval rested on a single open-label Phase 2/3 trial enrolling 10 patients with genetically confirmed CHAPLE disease, aged 3 to 19 at enrollment (median 8.5 years) — effectively the entire identified treatable population the trial could realistically recruit at the time. Patients received a single 30 mg/kg intravenous loading dose on day 1, followed by once-weekly, weight-tiered subcutaneous maintenance dosing. All 10 patients achieved normalization of serum albumin concentration by week 12 and maintained it through at least 72 weeks of treatment, alongside normalized serum IgG levels and documented reductions in hospitalizations and albumin/immunoglobulin transfusions compared to each patient's own pre-treatment history (Ozen A, and the Pozelimab CHAPLE Working Group, "Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study," Lancet 2024;403(10427):645-656, PMID 38278170, DOI: 10.1016/S0140-6736(23)02358-9).1 There was no placebo group and no active comparator — every patient in the trial received pozelimab, and the drug's effect was judged against each patient's own pre-treatment disease course and published natural-history data rather than a concurrently randomized control arm.
Why the FDA accepted a trial this small
An evidentiary bar this low is the exception, not the rule
A 10-patient, open-label, single-arm trial with no internal control group is a genuinely unusual basis for FDA approval — this site's other Library pages describe far larger, randomized, typically placebo- or active-controlled trials as the normal evidentiary standard. CHAPLE disease's own documented natural history is what made the FDA's acceptance of this design defensible rather than a lowering of the bar for its own sake: published case series describe the untreated disease as severe, progressive and, in a meaningful share of cases, fatal in childhood from complications of chronic protein loss or thrombosis, in a population small enough (fewer than 10 identified US patients at approval) that randomizing even half of them to a placebo arm would have meant knowingly withholding a plausible treatment from patients with a life-threatening disease and no other options. The FDA granted pozelimab Priority Review, Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations, and the trial's consistent, sustained biomarker normalization across all 10 patients — rather than a mixed or partial response — gave the agency a genuinely strong within-patient signal despite the small numbers. This is a real, documented instance of the FDA calibrating its evidentiary standard to a disease population too small for a conventional trial to exist at all, not a template that applies to drugs for more common conditions.
The same class-wide meningococcal risk
Like every other approved anti-C5 antibody this site covers, pozelimab carries a boxed warning for serious and potentially fatal Neisseria meningitidis infection, a direct consequence of blocking terminal complement activity — the same immune pathway the body normally relies on to help clear that bacterium. Veopoz's label requires patients to complete or update meningococcal vaccination against serogroups A, C, W, Y and B at least 2 weeks before the first dose wherever possible, following current ACIP guidance for patients on a complement inhibitor, and prescribers give every patient a wallet-card-style Patient Safety Card describing meningococcal-infection symptoms to carry for the duration of treatment and for three months after the last dose — the same underlying vaccination-and-monitoring discipline this site's eculizumab & ravulizumab, crovalimab and zilucoplan pages describe for their own C5-pathway drugs. Vaccination reduces but does not eliminate the risk of meningococcal infection in patients on any complement-C5 inhibitor.
Current status
Veopoz remains FDA-approved and is the only approved treatment for CHAPLE disease anywhere in the world as of this review; Regeneron markets it directly in the US. It has not yet received European Medicines Agency marketing authorization — as of mid-2025, the EMA's most recent public action on pozelimab was accepting a modification to its agreed pediatric investigation plan, a regulatory step that precedes a full marketing-authorization filing rather than one that grants it. As an extremely narrow, single-indication biologic for a disease affecting a handful of identified patients worldwide, Veopoz carries no wellness, off-label or grey-market interest of any kind — the same pattern this site's other ultra-rare-disease enzyme and antibody pages describe.
References
- FDA approval of Veopoz (pozelimab-bbfg, BLA 761339, Regeneron Pharmaceuticals), 18 August 2023, for CD55-deficient protein-losing enteropathy (CHAPLE disease) in patients 1 year of age and older — cross-checked against Regeneron press releases, the FDA-approved prescribing information (accessdata.fda.gov), and contemporaneous trade coverage (HCPLive, Pharmacy Times, Global Genes).
- Ozen A, and the Pozelimab CHAPLE Working Group, "Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study," Lancet 2024;403(10427):645-656, PMID 38278170, DOI: 10.1016/S0140-6736(23)02358-9 — 10 patients, open-label, no placebo arm; all 10 achieved normal serum albumin by week 12, sustained through 72 weeks.
- FDA Priority Review, Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations for pozelimab, per Regeneron's FDA approval announcement and the FDA's own Breakthrough Therapy designation database; Veopoz (pozelimab-bbfg) FDA-approved prescribing information, dosing regimen (30 mg/kg IV loading dose, then weekly weight-tiered subcutaneous maintenance) — accessdata.fda.gov, label 761339s000lbl.pdf.
- Veopoz (pozelimab-bbfg) FDA-approved prescribing information, Boxed Warning section on serious meningococcal infection, meningococcal vaccination requirements per current ACIP guidance, and the Patient Safety Card requirement, current as of this review; cross-checked against DailyMed labeling.
- European Medicines Agency decision accepting a modification of the agreed paediatric investigation plan for pozelimab, 4 August 2025 (EMA/PIP procedure EMA-PE-0000257243) — no EU marketing authorization for pozelimab/Veopoz had been granted as of that filing; cross-checked against the EMA's public paediatric investigation plan register.